Replies to post #34349 on Revive Therapeutics Ltd (RVVTF)

[tripmcneely]

Scares me that this gets more likely

[PennyWorld]

Last year my predictions were that we won't hear anything of material value (regarding EUA) until summer 2023. With this whole Type C related meeting regarding revising protocol endpoints, summer 2023 may be too optimistic. Assuming the new endpoints are approved, if the FDA requires an extension of the Phase 3 trial then we are looking at EOY. Once the trial is officially complete it will take them 60-90 days to gather/compile/analyze the data and to format it all into an EUA application. Then add another 3-6 months for the FDA to make a decision. I don't think the pps will hold up that long considering Delta Covid is behind us (China is a communist nation outlier).

Now hospitals are typically talking flu, RSV and covid in the same breath. For the most part, covid is turning into just another flu-like virus. I just had COVID and the paxlovid pill knocked it out in less than 48 hours (and I'm in the high risk group).

EUA is designed for 'emergency use', so the FDA now has tightened up approval requirements. Covid SOC today is dramatically better than what it was 2 years ago. China is an exception because they are a communist closed-door country who hides everything they do from the ROW. They do not represent the norm. JMHO

[govprs]

Man the raise is so necessary here and the utter failure is a sign.

[Ecomike]

Any fool that sells for less than .15 right now deserves ass-whoppin-loss IMO.

Covid19 said "I'LL BE bach" and it is, with a vengence. Sellers better hurry up and reaload at the ask... $$$ land cometh this year IMO..

"COVID hospital admissions rising quickly in NY where XBB.1.5 is the new dominant variant."

A few weeks ago, almost no one had heard of it yet (except me and those that follow closely) "Omicron subvariant, XBB.1.5, is on the increase and has now been identified in more than 25 countries. " It will be all over the news the rest of this winter.

COVID hospital admissions rising quickly in NY where XBB.1.5 is the dominant variant. This from @nytimes: We don't yet have the breakdown for hospitalizations for those who did or did not get their bivalent booster, but as of Oct last yr 18.6X decreased risk for those who did pic.twitter.com/uQtpY0TU3Q

— Prof Peter Hotez MD PhD (@PeterHotez) January 6, 2023